drugset / Trial / NCT04234191

Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

NCT04234191

RandomizedParallel-groupOpen-labelTreatment

Summary

The current first-line treatment for opioid use disorder (OUD) in Canada is buprenorphine/naloxone (bup/nx). The standard induction method of bup/nx requires patients to be abstinent from opioids and thereby experience withdrawal symptoms prior to induction, which can be a major barrier in starting treatment. Rapid micro-induction (also known as micro-dosing, low-dose induction) involves the administration of small, frequent does of bup/nx and removes the need for a period of withdrawal prior to the start of treatment. This study aims to compare the effectiveness and safety of rapid micro-induction versus standard induction of bup/nx in patients with OUD.

Timeline

Start
2021-08-18
Primary completion
2025-01
Completion
2025-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine/naloxone Unknown 0.5 mg Other
Subject Buprenorphine/naloxone Unknown 1 mg Other
Subject Buprenorphine/naloxone Unknown 2 mg Other
Subject Buprenorphine/naloxone Unknown 4 mg Other
Subject Buprenorphine/naloxone Unknown 8 mg Other
Subject Buprenorphine/naloxone Unknown 32 mg Other
Background Hydromorphone Other / unclassified 1 mg Oral
Background Hydromorphone Other / unclassified 48 mg Oral

Indications